<DOC>
	<DOCNO>NCT00786552</DOCNO>
	<brief_summary>The aim trial evaluate efficacy tolerability pemetrexed + paclitaxel patient recurrent/advanced follicular , papillary anaplastic thyroid cancer .</brief_summary>
	<brief_title>Pemetrexed + Paclitaxel Patients With Recurrent/Advanced Thyroid Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Thyroid Carcinoma , Anaplastic</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Diagnosis metastatic , histologically proven follicular/papillary anaplastic thyroid cancer without clinically meaningful surgical radiotherapeutic option and/or amenability radioiodine therapy evidence progressive symptomatic disease . No form chemotherapy investigational anticancer agent therapy least 4 week enrollment study . Performance status 0 2 ECOG scale . Evidence measurable disease accord RECIST criterion . Prior radiation therapy surgery allow complete least 2 week prior study enrollment , prior radioiodine treatment least 3 month prior study enrollment patient must recover acute toxic effect treatment prior study entry . Adequate organ function . No active infection ( discretion investigator ) current central nervous system ( CNS ) metastases history central nervous system metastases serious concomitant systemic disorder incompatible study ( discretion investigator ) . No breast feeding pregnancy . For woman childbearing potential negative serum pregnancytest perform 7 day prior inclusion study . No coexist second malignancy history prior malignancy within last 5 year . ( Excluding basal squamous cell carcinoma skin , superficial bladder cancer situ carcinoma cervix evidence recurrence ) . For men woman childbearing potential appropriate contraceptive precaution take trial 3 month afterwards . No significant cardiovascular disease form abnormal electrocardiogram ( ECG ) couple clinical feature recent recurrent symptomatic cardiac disease ( include myocardial infarction within last year , uncontrolled angina , arrhythmia hypertension , severe congestive heart failure ( NYHA &gt; 3 ) ) . No evidence peripheral neuropathy great CTC Grade 1 . No prior taxane and/or pemetrexed therapy . Ability discontinue administration acetysalicylate nonsteroidal antiinflammatory agent ( NSAID ) 2 day , day , 2 day dose pemetrexed ( 5 day prior longacting agent piroxicam ) . Exceptions selective cyclooxygenase IIinhibitors analgesic treatment may discuss . No clinically significant effusion ( pleural peritoneal ) , albumin &lt; 2.5 g/dl time study treatment application . The drainage effusion prior study treatment application possible . Inability oral intake folic acid intramuscular vitamin B12 supplementation . At least 18 year age absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial Before patient registration/randomization , write informed consent must give accord ICH/GCP , national/local regulation . Participation another trial time allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>recurrent/advanced thyroid cancer</keyword>
	<keyword>papillary anaplastic thyroid cancer</keyword>
</DOC>